Gout, Xanthine Oxidase Inhibition, and Cardiovascular Outcomes

Circulation. 2018 Sep 11;138(11):1127-1129. doi: 10.1161/CIRCULATIONAHA.118.036148.
No abstract available

Keywords: Editorials; allopurinol; cardiovascular outcomes; clinical trial; febuxostat; gout.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Aged
  • Allopurinol
  • Cardiovascular Diseases*
  • Febuxostat
  • Gout Suppressants
  • Gout*
  • Humans
  • Risk Factors
  • Xanthine Oxidase

Substances

  • Gout Suppressants
  • Febuxostat
  • Allopurinol
  • Xanthine Oxidase